Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 5/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | BAX | Q07812 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261023 | 0.86 | ALDH1A1 (0.54) | CA1CA2TDP1L3MBTL1ALDH1A1 | |
| SCHEMBL177644 | 0.84 | KCNH2 (0.41) | CA1CA2ALDH1A1ACHE | |
| SCHEMBL3789064 | 0.81 | CA1 (0.55) | CA1CA2LTA4HNR1H2BAX | |
| SCHEMBL13857858 | 0.80 | CA1 (0.53) | CA1CA2LTA4HNR1H2BAX | |
| SCHEMBL3790117 | 0.80 | CA1 (0.53) | CA1CA2LTA4HNR1H2BAX | |
| SCHEMBL30461111 | 0.80 | PARP15 (0.45) | L3MBTL1ALDH1A1 | |
| SCHEMBL10172394 | 0.80 | KMT2A (0.36) | CA1CA2L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2527374 | 0.80 | PARP15 (0.45) | L3MBTL1ALDH1A1 | |
| SCHEMBL30461110 | 0.80 | PARP15 (0.45) | L3MBTL1ALDH1A1 | |
| SCHEMBL4454151 | 0.78 | LTA4H (0.55) | LTA4HNR1H2BAXTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122778-A1 | PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS | GOSSAMER BIO SERVICES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122778-A1 | PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS | GOSSAMER BIO SERVICES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| EP-3147285-A2 | PURINONE COMPOUNDS AS KINASE INHIBITORS | Pharmacyclics, Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| CN-106279172-A | Purinone compound as inhibitors of kinases | 药品循环有限责任公司 | 2017-01-04 | — | — | CN | disclosed |
| US-20160368924-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-20160368924-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-20160368924-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-9469642-B2 | Purinone compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469642-B2 | Purinone compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469642-B2 | Purinone compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2016-10-18 | — | — | US | disclosed |
| CN-104640861-B | Purinone compounds as kinase inhibitors | 药品循环公司 | 2016-08-24 | — | — | CN | disclosed |
| CN-104640861-A | Purinone compounds as kinase inhibitors | PHARMACYCLICS INC | 2015-05-20 | — | — | CN | disclosed |
| US-20140378446-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140378446-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140378446-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| EP-2809672-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | Pharmacyclics, Inc. (US) | 2014-12-10 | — | — | EP | disclosed |
| WO-2013116382-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368924-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, BCL9 | CA1 4864/4885CA2 4642/4885LTA4H 1886/4885 |
| US-20140378446-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, BCL9 | CA1 4864/4885CA2 4642/4885LTA4H 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.